This page is intended to provide access to U.S. Securities and Exchange Commission (SEC) filings for MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on central nervous system disorders. While no specific filings are listed in the available data here, as a Nasdaq-listed issuer MapLight has described an initial public offering and a concurrent private placement conducted under an effective registration statement filed with the SEC.
In general, SEC filings for a company like MapLight can include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe material events such as clinical trial updates, financing transactions, or significant collaborations. Registration statements and prospectuses related to offerings, such as the IPO MapLight has referenced, also form part of the company’s regulatory record.
For a clinical-stage biopharmaceutical company, these filings typically discuss the status of product candidates like ML-007C-MA, ML-004, ML-021 and ML-009, outline clinical development plans, and describe risk factors related to central nervous system drug development. They may also provide details on research and development expenses, cash resources from offerings and private placements, and other financial information.
Stock Titan’s platform enhances access to such documents by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries. These tools are designed to help readers interpret lengthy filings, highlight key topics such as clinical trial disclosures, financing terms, and collaboration agreements, and locate information about insider transactions reported on Form 4 when available.
MapLight Therapeutics, Inc. officer Lillie James Woodruff reported 4,896 common shares for sale, with an aggregate market value of $132,289.92; the approximate sale date is April 15, 2026. The shares are to be sold solely to satisfy tax-withholding obligations in connection with restricted stock unit (RSU) vesting.
MapLight Therapeutics, Inc. (MPLT) reported a proposed sale by its officer Kristopher Hanson of 1,827 common shares, with an aggregate market value of $49,365.54 and an approximate sale date of April 15, 2026. The notice states the shares are to be sold solely to satisfy tax-withholding obligations in connection with restricted stock unit vesting.
MapLight Therapeutics, Inc. officer Christopher A. Kroeger reported a proposed sale of 20,822 common shares, with an aggregate market value of $562,610.44 and an approximate sale date of April 15, 2026. The shares are to be sold solely to satisfy tax-withholding obligations in connection with RSU vesting. The notice lists restricted stock unit grants of 14,844, 7,664 and 24,222 shares on July 30, 2023, November 9, 2023, and May 2, 2024, respectively.
Maplight Therapeutics, Inc. submission lists proposed sales of Common Stock under Form 144. The excerpt shows Restricted Stock Unit grants of 3,200 shares (07/30/2023), 1,434 shares (11/09/2023), and 6,147 shares (05/02/2024). A securities line also shows the numbers 4,896, 132,289.92, and 42,440,000 with an apparent date of 04/15/2026.
MapLight Therapeutics, Inc. officer Kristopher Hanson gave notice of a proposed sale of 1,827 common shares, with an aggregate market value of $49,365.54 and an approximate sale date of April 15, 2026. Jefferies LLC is listed as the broker. The shares listed for sale were acquired through restricted stock unit grants: 1,668 shares on July 30, 2023, 853 shares on November 9, 2023, and 3,012 shares on May 2, 2024.
Maplight Therapeutics filed a Form 144 notifying an intended sale of 3,472 shares of common stock through Jefferies LLC. The filing also lists a dollar figure of $93,813.44 and 42,440,000 shares outstanding as of 04/15/2026. The excerpt shows recent Restricted Stock Unit Grants of 3,348, 1,545, and 6,350 shares with grant/vesting dates noted.
MapLight Therapeutics details its clinical-stage CNS drug pipeline and discovery platform focused on debilitating brain disorders. The company’s lead candidate, ML-007C-MA, is an M1/M4 muscarinic agonist–antagonist combo in Phase 2 trials for schizophrenia (ZEPHYR) and Alzheimer’s disease psychosis (VISTA), with FDA Fast Track for hallucinations and delusions in ADP.
ML-007C-MA aims to match central efficacy with reduced peripheral side effects, supported by four Phase 1 studies in 270 participants. A second program, ML-004, repurposes zolmitriptan in an IR/ER tablet for autism spectrum disorder, now in a Phase 2 IRIS trial targeting social communication deficits and irritability.
The pipeline also includes three preclinical programs (ML-009, ML-055, ML-021) built on a circuit-based neuroscience platform using optogenetics and advanced transcriptomics. As of December 31, 2025, MapLight reports a broad patent estate covering its clinical and preclinical assets and retains global rights to all programs.
MapLight Therapeutics reported a net loss of $161.2 million for 2025, wider than $77.6 million in 2024, as it accelerated clinical development. Research and development expenses rose to $138.3 million from $68.5 million, and general and administrative expenses increased to $30.7 million from $14.4 million.
The company ended 2025 with $453.1 million in cash, cash equivalents and investments and expects this to fund operations through 2027. Total assets were $479.5 million and total liabilities were $21.1 million, resulting in stockholders’ equity of $458.4 million.
MapLight highlighted several near- and mid-term catalysts. Its Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia is expected to complete enrollment in April 2026, with topline data in the third quarter of 2026. The Phase 2 IRIS trial of ML-004 in autism spectrum disorder has completed enrollment, also targeting topline data in the third quarter of 2026. ML-007C-MA received FDA Fast Track designation for Alzheimer’s disease psychosis, with Phase 2 VISTA topline results anticipated in the second half of 2027, and the earlier-stage ML-055 program is expected to reach preclinical candidate nomination in 2026.